Kymera Therapeutics Inc (KYMR NASDAQ) stock market data APIs
$61.8372
-1.65(-2.7%)
as of October 31, 2025
Try our APIs with
free plan!
Kymera Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Prev. Close
61.8372
Open
60.188
High
62.654
Low
59.9818
52 wk Range
19.445-63.9599
Market Cap
4 393 M
Shares Outstanding
71 498 K
Revenue
44 711 K
Beta
2.27
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kymera Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kymera Therapeutics Inc data using free add-ons & libraries
Get Kymera Therapeutics Inc Fundamental Data
Kymera Therapeutics Inc Fundamental data includes:
- Net Revenue: 44 711 K
- EBITDA: -305 056 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: -0.8613
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kymera Therapeutics Inc News
New
Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases
Kymera Therapeutics (KYMR) just unveiled new preclinical data for its candidate KT-579 at the American College of Rheumatology Annual Meeting. This announcement has sparked renewed interest among inve...
How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA
Kymera Therapeutics recently presented new preclinical data for its oral IRF5 degrader KT-579 at the American College of Rheumatology 2025 meeting, showing disease-modifying activity in lupus and rheu...
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicin...
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
Kymera Therapeutics, Inc. WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
